Advanced Filters
noise

Beijing, China Clinical Trials

A listing of Beijing, China clinical trials actively recruiting patients volunteers.

Found 2,326 clinical trials
X Xiang Y Zhang, M.D.,Ph.D

Study on the Efficacy Mechanism of Natural Psychotherapy for Neurosis

We explore objective indicators of the efficacy of natural psychotherapy in the treatment of disorders such as obsessive-compulsive disorder

15 - 50 years of age All Phase N/A
T TAO OUYANG, M.D

Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

This study is a one-arm, open, phase II clinical study, and the study subjects are locally advanced and inflammatoryPatients with sexual or early HER2-positive breast cancer entered the trial period after signing informed consentTo evaluate trastuzumab combined with pyrrolitinib and chemotherapy regimen (TCbH+Py) for HER2 positive breastPathologic complete response rate …

18 - 70 years of age Female Phase 2
W Weihai Ning, Dr.

Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma

This is a single-arm, single-center, drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in progressive DIPG patients (NCI-CTCAE V5.0).

1 - 18 years of age All Phase 1
B Bo Lan, MD.

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

Radiation therapy is a crucial part in the comprehensive treatment of breast cancer. In recent years, emerging systemic treatment regimens such as HER 2 inhibitors, CDK 4/6 inhibitors, PARP inhibitors, capecitabine and PD1 inhibitors have greatly improved the prognosis of breast cancer and has become the standard treatment for specific …

18 - 70 years of age Female Phase N/A
F Fangfang Lv, MD

Phase Ib Clinical Study of Keynatinib

The purpose of this study is to evaluate the efficacy, safety, PK characteristics in subjects with relapsed/refractory B-cell lymphoma. Furthermore, the relationship between the exposure level of Keynatinib and its efficacy and safety, the penetration rate of keynatinib in the Blood-Brain Barrier (BBB) and its PK characteristics in cerebrospinal fluid …

18 years of age All Phase 1

PRO1184 for Advanced Solid Tumors

This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1184 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

18 years of age All Phase 1/2
J Jun Guo, Director

OH2 Injection in Solid Tumors

This phase I study evaluates the safety and efficacy of OH2 as single agent or in combination with Keytruda, an anti-PD-1 antibody, in patients with malignant solid tumors (Melanoma). OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus …

18 - 75 years of age All Phase 1/2
W Wenbin Qian

Chidamide Bridging for CAR-T Therapy

The previous research suggests that the low expression of NOXA protein may be an important biomarker for the treatment of drug resistance of chimeric antigen receptor-T (CAR-T) cells. Up regulating the expression of NOXA through histone deacetylase inhibitor (HDACi) can improve drug resistance and significantly improve the therapeutic effect of …

16 - 75 years of age All Phase 1/2

CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)

A phase II Study of CS0159 in Chinese patients with PSC(Primary Sclerosing Cholangitis)

18 - 75 years of age All Phase 2
H Huiming Guo, MD.

THE TRAVEL TRIAL: Transcatheter Right Atrial-ventricular Valve rEplacement With LuX-Valve

The trial aims to evaluate the safety and effectiveness of LuX-Valve transcatheter tricuspid valve and delivery system which are intended to use in symptomatic patients with severe tricuspid regurgitation and high surgical risk.

50 years of age All Phase N/A

Simplify language using AI